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Abstract 27 
Monogenic diabetes due to mutations in the transcription factor genes HNF1A and HNF4A is 28 
characterized by islet cell antibody negative, familial diabetes with residual insulin secretion. We 29 
report two sisters with childhood onset diabetes who are both heterozygous for the most common 30 
mutation in each of two transcription factors, hepatocyte nuclear factor 1A (HNF1A) and 31 
hepatocyte nuclear factor 4A (HNF4A).  The proband was diagnosed with diabetes at 7 years of 32 
age and treated with insulin for 4 years.  Her genetic diagnosis resulted in transition to 33 
sulfonylureas for one and a half years before insulin therapy was re-initiated due to declining 34 
glycemic control.  Her sister was diagnosed with diabetes at 14 years of age, treated initially with 35 
insulin but has been well controlled on oral sulfonylurea therapy for over two years. Both sisters 36 
inherited the HNF4A gene mutation R127W from their mother and the HNF1A gene mutation 37 
P291fsinsC (c.872dup) from their father.  The father was diagnosed with diabetes at 45 years of 38 
age. Their brother is heterozygous for the HNF4A R127W mutation. Both the brother and 39 
mother have normal glucose tolerance at the ages of 16 and 46 years, respectively. 40 
Digenic inheritance of HNF1A and HNF4A mutations is very rare and has only been reported in 41 
two families where conclusive evidence for the pathogenicity of their mutations was lacking.  42 
Follow-up studies in this family co-segregating the two most commonly reported  43 
HNF1A/HNF4A mutations will be informative for understanding the effect of digenic inheritance 44 
upon phenotypic severity and response to sulfonylurea therapy.     45 
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Introduction 50 
Monogenic diabetes including maturity onset diabetes of the young (MODY) results from 51 
mutations in single genes that regulate beta cell function and accounts for up to 5% of all 52 
diabetes cases in the US(1). Clinicians should consider a diagnosis of monogenic diabetes in lean 53 
youth with negative islet cell autoantibodies at diagnosis of diabetes, low insulin requirements 54 
and/or a family history of diabetes (2). The most common forms of monogenic diabetes involve 55 
mutations in hepatocyte nuclear factor 1A (HNF1A), glucokinase (GCK) and hepatocyte nuclear 56 
factor 4A (HNF4A) (2). 57 
The SEARCH for Diabetes in Youth study (SEARCH) is a multicenter, population-based study 58 
of youth with diabetes diagnosed under 20 years of age. In the SEARCH monogenic diabetes 59 
ancillary study, genomic DNA was sequenced for mutations in HNF1A and HNF4A in diabetes 60 
autoantibody negative participants enrolled in SEARCH between 2001 and 2006, if the fasting 61 
C-peptide concentration was >0.8ng/ml and stored DNA was available along with written 62 
consent for genetic testing. In one proband we identified a mutation in both the HNF1A and 63 
HNF4A genes. 64 
To date, there are two reports in the literature describing three individuals who have both HNF1A 65 
and HNF4A mutations. The first report describes an adolescent who inherited a different 66 
mutation from each parent while the second paper describes a mother and son with both 67 
mutations (3, 4).  We studied the genotypes and phenotypes within the family of a SEARCH 68 
participant with mutations identified in both HNF1A and HNF4A, in order to investigate the 69 
digenic inheritance within this family.  70 
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Case Report 72 
The proband is a 14 year old female who presented at 7 years of age with polyuria and polydipsia 73 
without ketoacidosis.  The diabetes autoantibody panel [glutamic acid decarboxylase-65 74 
(GAD65), insulinoma antigen-2 (IA-2), and insulin autoantibody (IAA)] performed at the 75 
Barbara Davis Center (Aurora,CO) at the time of initial presentation was negative.  A diagnosis 76 
of type 1 diabetes was made and she was treated with NPH and Regular insulin. 77 
On recruitment to SEARCH, at the age of 8 years, she was well controlled on 0.3 units/kg/day of 78 
insulin with a hemoglobinA1c (HbA1c) of 5.9% (reference range: 3.9-6.1%). Her fasting C-79 
peptide was 0.86 ng/mL (reference range: 0.5-3 ng/dL) and 60-minute stimulated C-peptide was 80 
1.96 ng/mL. Due to the negative diabetes autoantibody panel, she underwent genetic testing as 81 
part of the SEARCH monogenic diabetes ancillary study at 11 years of age demonstrating a 82 
heterozygous missense mutation in exon 4 of HNF4A, R127W (c.379C>T) and a heterozygous 83 
frameshift mutation in exon 4 of HNF1A, P291fsinsC (c.872dup). Insulin therapy was 84 
completely discontinued and she was started on glipizide (1.25 mg once daily) with the dose 85 
titrated to 2.5 mg once daily based on blood sugar checks, with weekly blood sugar reviews and 86 
close support from a diabetes specialist nurse practitioner. There was no significant change in her 87 
glycemic control (HbA1c was 6.5% before and 6 months after; reference range: 3.5-6.3%). 88 
However, 21 months after switching to glipizide, glycemic control worsened (HbA1c: 8.6%) 89 
despite increasing doses of glipizide, necessitating re-initiation of insulin therapy.  Currently, at 90 
14.5 years of age, she is receiving 0.4 units/kg/day of insulin as NPH and Regular, and glipizide 91 
10 mg/day, with an HbA1c of 6.8%. The choice of NPH and Regular insulin was based on 92 
parental request. 93 
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Prior to the identification of the gene mutations in the proband, hyperglycemia was detected in 94 
the proband’s sister at 14 years of age during a routine well-child examination. She was 95 
asymptomatic. A diagnosis of type 1 diabetes was made and NPH and Regular insulin therapy 96 
(0.3 units/kg/day) was initiated.  Due to the findings in the proband, the sister also underwent 97 
genetic testing as part of the SEARCH monogenic study and was also found to be heterozygous 98 
for both the HNF1A and HNF4A mutations. Insulin was discontinued and glipizide therapy was 99 
initiated and titrated with improvement in glycemic control (HbA1c decreased from 8.7% to 100 
5.8%, 5 months after; reference range: 3.5-6.3%). She has remained on extended release 101 
glipizide 2.5 mg/day for the past 27 months with a recent HbA1c of 6.1%.  102 
The proband’s father was known to be “borderline diabetic”.  His oral glucose tolerance test 103 
(OGTT) confirmed the presence of diabetes (fasting glucose 92 mg/dL and 2-hour glucose of 104 
215 mg/dL). Genetic testing revealed heterozygosity for the P291fsinsC HNF1A mutation. The 105 
paternal grandfather was diagnosed with diabetes at age 65 years but was not available for 106 
genetic testing. Paternal great-grandfather was reported to have diabetes since the age of 20 years 107 
but lived to the age of 82 years (see Figure 1). 108 
The proband’s mother was asymptomatic at 45 years of age and an OGTT showed a fasting 109 
plasma glucose of 97mg/dl and a 2-hour value of 117 mg/dl, consistent with normal glucose 110 
tolerance.  Genetic testing revealed the R127W mutation in HNF4A. She did not have gestational 111 
diabetes mellitus during any of her three pregnancies. Her extended family refused genetic 112 
testing. Testing of the proband’s brother demonstrated the same HNF4A mutation as the mother 113 
and a normal OGTT result (fasting plasma glucose 98 mg/dL and 2-hour value 123 mg/dL). All 114 
family members were lean with underweight or normal body mass index (BMI).   115 
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Discussion 116 
In the family described in this report, we identified two separate transcription factor MODY 117 
mutations, both reported in previous studies as pathogenic mutations.  The HNF1A P291fsinsC 118 
(c.872dup) mutation is the most common mutation causing HNF1A-MODY, described in 234 119 
families and the HNF4A R127W mutation is the most common mutation causing HNF4A-120 
MODY, described in 15 families throughout the world (5)(Colclough K et al. 2012, submitted to 121 
Human Mutation). Digenic cases are likely to be very rare, but may be under ascertained due to 122 
sequential gene testing in molecular genetic laboratories meaning that if an HNF1A mutation is 123 
found, HNF4A analysis is not undertaken. Simultaneous mutation testing of multiple genes by 124 
next generation sequencing will reveal the true prevalence of digenic inheritance in MODY. 125 
In the previous reports of families with two transcription factor mutations the evidence for the 126 
pathogenicity of both mutations is inconclusive. The mother and son reported by Beijers et al.(4) 127 
were heterozygous for HNF1A G31D and HNF4A H214Y, but the G31D substitution has 128 
subsequently been identified in 7/4300 European exomes (Exome variant server, NHLBI GO 129 
Exome Sequencing Project http://evs.gs.washington.edu/EVS/). It is therefore unlikely to be 130 
causative of MODY. The proband described by Forlani et al.(3) was heterozygous for HNF1A 131 
E508K and HNF4A R80Q. Both mutations are novel and whilst a different mutation, R80W, has 132 
been reported in HNF4A (6), further evidence to support the pathogenicity of E508K is lacking.  133 
The siblings we describe with the HNF1A P291fsinsC and HNF4A R127W mutations are the 134 
first cases of digenic transcription factor MODY where both mutations have previously been 135 
reported as being pathogenic. The HNF1A P291fsinsC (c.872dup) mutation is the most common 136 
of all MODY mutations: it results in a frameshift and premature termination codon. There is no 137 
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doubt over its pathogenicity and both sisters had inherited this mutation from their diabetic 138 
father. The HNF4A R127W mutation was first described by Furuta et al. in 1997(7) and is the 139 
most common HNF4A mutation, reported in the literature in 15 families from multiple countries. 140 
The R127W mutation is a missense mutation which is thought to retain 50% of the wild-type 141 
activity without dominant negative effect (8). Initial functional studies failed to demonstrate an 142 
effect upon transcriptional activation(9) but other in vitro assays showed decreased DNA binding 143 
and reduced transcriptional activation. (8, 10)  Interestingly HNF4A R127W has recently been 144 
identified in 1/4300 European exomes (Exome Variant Server, NHLBI GO Exome Sequencing 145 
Project, http://evs.gs.washington.edu/EVS/). This could be a chance finding of an individual 146 
predisposed to MODY or a suggestion that the R127W mutation may not cause monogenic 147 
diabetes. Additional data from exome sequencing in large cohorts is required for conclusive 148 
proof of the pathogenicity of this mutation. 149 
The absence of a maternal family history of diabetes may be explained by a de novo mutation in 150 
the mother, particularly since de novo mutations are more common in the HNF4A gene 151 
compared to HNF1A(6). Unfortunately, the mother’s family was not available for genetic testing. 152 
The age at diagnosis of diabetes in patients with MODY varies considerably (from 4 to 77 years 153 
for patients with HNF1A or HNF4A mutations in the Exeter cohort) and is influenced by type 2 154 
diabetes risk variants(11), intrauterine hyperglycemia(12) and mutation type or location(13). The 155 
proband and her sister described in this study were diagnosed at 7 and 14 years respectively. 156 
Whilst we might speculate that digenic inheritance could cause earlier onset of diabetes,  the 157 
mean age at diagnosis for individuals within the SEARCH study with single gene mutations is 12 158 
years (HNF1A) and 11 years (HNF4A) (Gilliam LK et al. 2012, submitted to Diabetes Care). A 159 
good response to sulfonylurea therapy is a characteristic of HNF1A/4A MODY (14, 15). While 160 
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both siblings with digenic mutations responded to sulfonylureas in the short term, one re-started 161 
insulin after 18 months due to deterioration in glycemic control. Thus, long term studies are 162 
required to assess eventual insulin requirement in patients with digenic diabetes.   163 
  164 
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Table 1: Clinical Features and Mutations in First-degree Relatives 235 
 
Current Age  
(years) 
Age at 
diagnosis of 
diabetes 
(years) 
HNF 1A 
mutation 
HNF 4A 
mutation 
Term Birth  
weights 
(kg)  
BMI 
(kg/m2) 
Proband 14 7 P291fsinsC/N R127W/N 3.37 16.5 
Sister 16 14 P291fsinsC/N R127W/N 4.11 17.7 
Brother 18 - N/N R127W/N 3.26 17.3 
Mother 48 - N/N R127W/N 2.75 18.9 
Father 47 45 P291fsinsC/N N/N 3.01 21.5 
 236 
  237 
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Figure1. Pedigree chart of family depicting family history of diabetes 238 
 239 
 240 
 241 
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